SkyShowtime Announces Official Launch Date and Content Line-Up
14.9.2022 17:56:00 EEST | Business Wire | Press release
New streaming service SkyShowtime today announced that it will officially launch on 20 September 2022, bringing its premium offering of exclusive and iconic entertainment to millions of homes across Europe for the first time.
A joint venture of Comcast (NASDAQ: CMCSA) —parent company of NBCUniversal and Sky— and Paramount Global (NASDAQ: PARA, PARAA), SkyShowtime will launch in Denmark, Finland, Norway and Sweden on 20 September, before expanding into the Netherlands later this year in Q4. SkyShowtime will continue its roll out across Spain, Portugal, Andorra, and Central & Eastern Europe (CEE) over the coming months and through Q1 2023. CEE markets include Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Kosovo, Montenegro, North Macedonia, Poland, Romania, Serbia, Slovakia and Slovenia. Specific launch dates and pricing in these markets will be announced in the coming months.
SkyShowtime brings together the best entertainment from the world’s greatest studios and storytellers. Featuring thousands of hours of quality entertainment for the whole family, the service will be home to a wide selection of the world’s most highly anticipated series and movies.
It will feature the exclusive television premieres of first-run theatrical films from Paramount Pictures and Universal Pictures, Hollywood’s two oldest studios and which together account for nearly 50% of Hollywood box office.
SkyShowtime will be the home to a selection of new blockbuster films following their theatrical and home entertainment release, including Top Gun: Maverick, Jurassic World Dominion, Minions: The Rise of Gru, The Northman, Sing 2, Sonic the Hedgehog 2, The Lost City, Downton Abbey: A New Era, Nope, Belfast, Ambulance and The Bad Guys.
In addition, SkyShowtime features new premium scripted series, kids and family content and a selection of iconic library titles and box sets from Universal Pictures, Paramount Pictures, Nickelodeon, DreamWorks Animation, Paramount+, SHOWTIME®, Sky Studios and Peacock - all streaming in one place. SkyShowtime will also feature local original programming, documentaries and specials from its markets.
In the Nordics, as part of the partnership with Paramount, SkyShowtime will replace Paramount+, allowing existing and future customers to watch current Paramount+ favourites such as Halo, Yellowstone, The Offer and Star Trek: Strange New Worlds, as well as SHOWTIME® originals Yellowjackets, Dexter: New Blood, Super Pumped: The Battle for Uber, and The First Lady. And for the first time, subscribers will gain access to even more new and exclusive premium series and movies spanning the best of Universal Pictures, Sky Originals and NBCUniversal.
From launch, customers can watch series premieres of highly anticipated SHOWTIME® drama American Gigolo, Sky Originals The Rising, The Fear Index, and The Midwich Cuckoos, as well as Law & Order Season 21 from Peacock. Over the coming months, additional series premieres will include Yellowstone Season 5, Pitch Perfect: Bumper in Berlin, Vampire Academy and SHOWTIME® series Yellowjackets Season 2 and Let The Right One In.
SkyShowtime CEO Monty Sarhan said: “It’s time… for SkyShowtime, — the next great streaming service for Europe. Just months after receiving full regulatory approval, SkyShowtime will officially launch on 20 September 2022. We’re excited for our customers to have exclusive access to the latest series and movie premieres from our iconic and world-renowned studios. We look forward to sharing further details about launch dates for our other markets and bringing SkyShowtime to even more people across Europe.”
SkyShowtime Regional General Manager for Northern Europe Henriette Skov commented: “We’re thrilled to launch SkyShowtime across the Nordics and look forward to offering our customers the very best selection of global series and movies all in one place.”
The service will be available direct-to-consumer via the SkyShowtime app across Apple iOS, tvOS, Android devices, and through the website: www.skyshowtime.com. SkyShowtime’s monthly price will be €6,99 in Finland, SEK 79 in Sweden, NOK 79 in Norway, and DKK 69 in Denmark.
SkyShowtime will also be available through the following distribution partners across its Nordic markets: Allente, RiksTV, Ruutu, Sappa, Strim, Telenor, Tele2, Telia, Telmore and YouSee from Nuuday Group, and TV 2 Play.
Powered by the Peacock platform, SkyShowtime was created specifically for Europe and is dedicated to these markets. With regional offices across its territories, SkyShowtime’s customer-centric focus and local market presence informs its approach to partnerships, content, and marketing. Once launched across more than 20 countries, SkyShowtime’s apps and content will be available in 18 different languages.
The content line up detailed in this press release is Nordic-specific and may vary per market.
For the trailer, please access here: https://youtu.be/ujzpT7FTeeY
For more details, please visit:
Website: www.skyshowtime.com
Newsroom: corporate.skyshowtime.com
LinkedIn: www.linkedin.com/company/skyshowtime
For further information, please email skyshowtimeenquiries@mcsaatchi.com
About SkyShowtime
SkyShowtime is a new streaming service that will launch in the Nordics on 20th September, this year.
A joint venture of Comcast Corporation (NASDAQ: CMCSA) and Paramount Global (NASDAQ: PARA, PARAA), SkyShowtime brings together the combined resources of both companies, direct-to-consumer experience, and the very best entertainment, movies, and original series from the iconic brands of Universal Pictures, DreamWorks, Sky Studios, Peacock, Paramount +, SHOWTIME®, Paramount Pictures and Nickelodeon.
SkyShowtime will be available in more than 20 European markets encompassing 90 million homes. It will be offered in Albania, Andorra, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Finland, Hungary, Kosovo, Montenegro, Netherlands, North Macedonia, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, and Sweden.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220905005022/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom